Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation

Table 1 Baseline characteristics

Characteristic	≥ 50% stenosis (n = 228)	< 50% stenosis (n = 400)
White/Caucasian (%)	81	85
Age (years)*	62 ± 12	56 ± 11
Past medical history (%)
Diabetes mellitus*	38	16
Hypertension*	67	54
Dyslipidemia*	63	40
Systolic blood pressure (mmHg)	138 ± 22	136 ± 21
Diastolic blood pressure (mmHg)	77 ± 11	77 ± 11
Body mass index (kg/m²)	29.1 ± 6.4	29.8 ± 6.8
Waist circumference (in)	36 ± 8	36 ± 7
Cigarette smoking (%)
Currently	22	19
Past	37	33
Menopausal status (%)*
Pre-menopausal	13	19
Peri-menopausal	4	10
Post-menopausal	82	70
Family history of premature CAD (%)	65	66
Current medication use (%)
Aspirin*	75	49
Statin*	37	22
ACE-inhibitor*	29	22
β-blocker*	50	34
History of HRT (%)*	40	54
CRP (n = 547; median, IQR)	0.37, 0.17–0.97	0.36, 0.16–0.84
SAA (n = 519; median, IQR)*	0.66, 0.36–1.15	0.55, 0.31–0.94
IL-6 (n = 547; median, IQR)	3.37, 1.85–6.87	2.79, 1.72–4.61

Abbreviations: ACE, angiotensin-converting enzyme; CAD, coronary artery disease; HRT, hormone replacement therapy; IQR, interquartile range; CRP, C-reactive protein; SAA, serum amyloid A; IL-6, interleukin-6
Values presented as means+SD unless otherwise specified
*P < 0.05 for comparison between > 50% stenosis and < 50% stenosis; for CRP, SAA, and IL-6 based on Wilcoxon rank-sum test
^†History of high cholesterol or use of lipid-lowering medication

ISSN: 1479-5876